

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 11 May 2004



THIS PAGE BLANK (USPTO)
BEST AVAILABLE COPY

THIS PAGE BLANK (USPTO)

Patents Act 1977
(Rule 16)

The Patent Office


1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH



1. Your Reference

AJT/MG/PJ3732

2. Patent application number

(The Patent office will fill in this part)

9918559.7

-7 AUG 1999

3. Full name, address and postcode of the or of each applicant (underline all surnames)

GLAXO WELLCOME KK
SHINJUKU MAYNDS TOWER
2-1-1, YOHOGI
SHIBUYA-KU
TOKYO 15108566
JAPAN

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its corporation

JP

07717135001

4 Title of the invention

NOVEL PHARMACEUTICAL FORMULATION

5 Name of your agent (if you know one)

ANDREW J TEUTEN
(SEE CONTINUATION SHEET)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

GLAXO WELLCOME PLC
GLAXO WELLCOME HOUSE, BERKELEY AVENUE
GREENFORD, MIDDLESEX
UB6 ONN, GB

Patents ADP number (if you know it)

07027683001

6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of Filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant a patent required in support of this request? (Answer yes if:

YES

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Patents Form 1/77

See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	1
Description	12
Claim(s)	2
Abstract	0
Drawing(s)	5 + 5

10. If you are also filing any of the following, state how many against each item

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patent Form 9/77)

Request for substantive examination (Patent Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature Andrew J Teuten

6 August 1999

AGENT FOR THE APPLICANTS

12. Name and daytime telephone number of person to contact in the United Kingdom

Kim Allen
0181-966 5721

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the patent Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been received

a) Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered "Yes" Patents Form 7/77 will need to be filed.
- d) Once you have filled in the form you must remember to sign and date it.
- e) For details of the fee and ways to pay please contact the Patent Office.

Additional Agents
(See Page 1 No. 5)

NAME(S)

Alan HESKETH
Michael ATKINSON
Karen CRAWLEY
Peter I. DOLTON
Hugh B. DAWSON
Wendy Anne FILLER
Ruth Elizabeth HACKETT
Catriona MacLeod HAMMER
Audrey HAMMETT
Graham M.H. LANE
Stephanie Anne LEAROYD
Helen Kaye QUILLIN
Michael A REED
Marion REES
Michael John STOTT
Andrew J. TEUTEN
Rachel M. THORNLEY
Janis Florence VOLCKMAN

ADDRESS

Glaxo Wellcome plc
Glaxo Wellcome House
Berkeley Avenue
Greenford
Middlesex
UB6 ONN
Great Britain

THIS PAGE BLANK (USPTO)

Novel Pharmaceutical Formulation

The present invention relates to an aqueous nasal formulation for use in the treatment of respiratory disorders.

5

Aerosol formulations are commonly used as effective anti-inflammatory treatments, but have implications with environmental safety. The most commonly used propellants in such formulations were previously chlorofluorocarbon containing (or CFC) propellants, however, these are currently being phased out,
10 following the 1987 Montreal Protocol Agreement.

Since then, safer hydrogen containing fluorocarbons have been used as propellants in aerosol formulations, but these are relatively expensive and the environmental impact of these new propellants has also been questioned.

15

Thus, there is a need for safe anti-inflammatory treatments such as aqueous nasal formulations. The corticosteroid beclomethasone dipropionate (9 α -chloro-16 β -methyl-1,4-pregnadiene-11 β , 17 α , 21-triol-3, 20-dione-17, α 21-dipropionate) is well known as a topical anti-inflammatory steroid and is found in aqueous
20 nasal formulations.

Prior aqueous nasal formulations containing beclomethasone dipropionate, used in treating such indications as allergic rhinitis (such as Beconase™ AQ) have utilised beclomethasone dipropionate monohydrate in addition to the following
25 constituents:

Anhydrous dextrose;
Avicel RC591 (Microcrystalline cellulose and
carboxymethylcellulose sodium);
Phenylethyl alcohol;
30 Benzalkonium chloride;

Polyoxyethylene (20) sorbitan monooleate;
and purified water

Beclomethasone dipropionate monohydrate is not currently licensed in all territories of the world (notably not in Japan) and as a consequence, nasal formulations containing such a medicament cannot be marketed in such territories without substantial research effort and expense. However, there is an alternative anhydrous form of beclomethasone dipropionate, previously used in a nasal formulation (eg. Aldecin™ AQ) which contains the following constituents:

Micronised beclomethasone dipropionate anhydrate;
Avicel RC591 (Microcrystalline cellulose and
carboxymethylcellulose sodium);
Glycerol;
Propylene glycol;
Polyoxyethylene (20) sorbitan monooleate;
and purified water.

However, in the absence of a sealed pressurised container, as with the propellant based delivery systems, these formulations may be prone to contamination. As a consequence, potentially harmful bacteria may contaminate the formulation and then be inhaled directly into the nasal cavity. Additionally, these formulations have also been known to cause irritancy, which is especially undesirable in respect of paediatric treatment.

Thus, according to the present invention we provide a pharmaceutical formulation which comprises an aqueous solution of carboxy methylcellulose sodium, glycerol, propylene glycol and polyoxyethylene (20) sorbitan monooleate, containing suspended therein particulate microcrystalline cellulose

and beclomethasone dipropionate anhydrate characterised in that said aqueous suspension further comprises:

Dextrose;
Phenylethyl alcohol;
Benzalkonium chloride;
Disodium hydrogen orthophosphate; and
Citric acid

The presence of dextrose, disodium hydrogen orthophosphate and citric acid is intended to overcome the irritancy problems associated with current anhydrous beclomethasone dipropionate formulations. This improvement is believed to be mediated through the dextrose acting as an isotonicity adjusting agent. Furthermore, the beclomethasone dipropionate anhydrate may be stabilised by appropriate selection of pH using disodium hydrogen orthophosphate and citric acid to act as a buffer.

In addition, phenylethyl alcohol and benzalkonium chloride are present within the formulation to act as preservatives.

Dextrose is preferably used as dextrose anhydrous. Disodium hydrogen orthophosphate is preferably used as disodium hydrogen orthophosphate anhydrous. Citric acid is preferably used as citric acid monohydrate. Microcrystalline cellulose and carboxy methylcellulose sodium is preferably used as the branded product Avicel RC591 (which typically contains 87-91% microcrystalline cellulose and 9 -13% carboxy methylcellulose sodium).

Particulate beclomethasone dipropionate anhydrate will suitably be micronised and have a mean particle size less than 20µm, preferably less than 10µm, especially 1-5µm.

Particulate microcrystalline cellulose will preferably have a particle size in the range 1 to 100µm.

5 A pharmaceutically acceptable amount of micronised beclomethasone dipropionate anhydrate is present within the formulation, which is preferably between 0.025-0.25% (w/w), especially 0.1% (w/w). The branded product Avicel RC591 and propylene glycol are suspending agents and are desirably added in a suitable amount to achieve this function, preferably between 1-5% and 0.1-20% (w/w) respectively, especially 1.5% and 1.0% (w/w) respectively.

10 We believe that Avicel RC591 acts as a suspending agent by imparting thixotropic properties to the formulation, wherein the formulation may become a stable suspension upon being stirred, shaken or otherwise disturbed. We similarly believe that propylene glycol aids stabilisation of the formulation by
15 reducing the bubbles which arise due to the presence of Avicel RC591 and benzalkonium chloride in the formulation.

Glycerol is added in a suitable amount to achieve its desired function as an excipient which reduces the solubility of beclomethasone dipropionate anhydrate
20 in formulation; preferably the amount of glycerol will be such as to make the beclomethasone dipropionate anhydrate essentially insoluble in the formulation. An amount of glycerol which is preferably between 0.1-6% (w/w), especially 4.0% (w/w) will be suitable. The wetting agent, polyoxyethylene (20) sorbitan monooleate (typically supplied as the branded product Polysorbate 80) is
25 desirably added in a sufficient quantity to achieve this function, preferably between 0.001-0.01% (w/w), especially 0.007% (w/w). The components disodium hydrogen orthophosphate anhydrous and citric acid monohydrate, which act as buffers, are desirably added in a suitable amount to achieve a final pH, following adjustment if necessary, of between 5 and 6, especially 5.5.
30 Suitable concentrations of each component are 0.01-0.4% and 0.01-0.2% (w/w)

respectively, especially 0.31% and 0.2% (w/w) respectively. Dextrose anhydrous is an isotonicity adjusting agent and is added in a suitable amount to achieve isotonicity with fluids of the nasal cavity. Suitable concentrations are between 0.1 and 5% (w/w), especially 5.0% w/w. Phenylethyl alcohol and benzalkonium chloride are preservatives which are preferably added in concentrations between 0.001-1% (v/w) and 0.001-1% (w/w) respectively, especially 0.275% (v/w) and 0.02% (w/w), respectively.

Besides its very good antiallergic properties and the above mentioned reduction in irritancy, the benefits of the invention may include the following:

Surprisingly, we have found that phenylethylalcohol has preservative properties by killing Pseudomonas cepacia (now known as Burkholderia cepacia) by a synergistic effect with benzalkonium chloride. Ps. cepacia is a bacterium which is capable of opportunistic infections such as blood poisoning and due to the bacterium being largely resistant to antibiotics, clinical treatment is complex. Results demonstrating this effect are shown in Figure 7.

A formulation of the present invention may be prepared by the manufacturing process according to the flow diagram shown in Figure 1.

A typical container suitable for a formulation of the present invention may be of the type exemplified in Figures 2 and 3. As a further aspect of the present invention we provide a container comprising a pharmaceutical formulation according to the present invention suitable for delivering it in the form of a nasal spray.

A suitable dosing regime for the formulation of the present invention would be for the patient to inhale deeply subsequent to the nasal cavity being cleared. During inhalation the formulation would be applied to one nostril while the other is

manually compressed. This procedure would then be repeated for the other nostril.

5 Wherein the patient is adult, two inhalations would be administered by the above procedure (100 μ g beclomethasone dipropionate anhydrate in total) four times each day.

10 Wherein the patient is a child, two inhalations would be administered by the above procedure (100 μ g beclomethasone dipropionate anhydrate in total) two times each day.

15 It will be appreciated that the above dosing regime should be adjusted according to the patient's age, body weight and/or symptom severity. However, the maximum daily dose should not exceed 16 inhalations for an adult and 8 inhalations for a child. If remission of the nasal symptoms is observed, the dose should be decreased as appropriate.

20 Examples of disease states in which the formulation of the present invention has potentially beneficial anti-inflammatory effects include allergies associated with the nasal cavity, more particularly allergic rhinitis.

25 Thus, according to a further aspect of the invention we provide a pharmaceutical formulation of the present invention for use in the treatment or prophylaxis of allergic rhinitis.

We also provide a use of a pharmaceutical formulation of the present invention in the manufacture of a medicament for the treatment or prophylaxis of allergic rhinitis.

More specifically, the formulation of the present invention may be illustrated by reference to the following example:

Example 1

5 A solution of propylene glycol (0.3kg) in purified water (23.6kg) is dispersed by mixing at 2000rpm for 5 mins. To this solution, dextrose anhydrate (1.5kg), phenylethyl alcohol (82.5g) and microcrystalline cellulose and carboxymethylcellulose sodium (Avicel RC591; 0.45kg) is then added separately
10 and mixed for a further 10, 5 and 30 mins, respectively. The dispersing is then ceased and the mixture is allowed to stand for 60 mins to hydrate. Dispersion is resumed at 3000rpm for 10 mins and then re-adjusted to 2000rpm.

15 Anhydrous disodium hydrogen orthophosphate (93g) is added to purified water (1.8kg) and dissolved by mixing at 3000rpm for 15 mins. This solution is then mixed into the dispersing suspension for 5 mins as is a solution of citric acid, prepared by manually mixing citric acid (0.06kg) with purified water (600g).

20 Glycerol (1.2kg) was heated at $48^{\circ}\text{C} \pm 2^{\circ}\text{C}$ and polyoxyethylene (20) sorbitan monooleate (Polysorbate 80; 2.1g) is then dissolved in the glycerol. A slurry is then formed by mixing micronised beclomethasone dipropionate anhydrate (30g) with the glycerol and polyoxyethylene (20) sorbitan monooleate solution at 4500rpm at $48^{\circ}\text{C} \pm 2^{\circ}\text{C}$ for 30 mins. This slurry is then added to the dispersing suspension and mixed for 15 mins.

25 A solution of benzalkonium chloride (50% w/v; 11.82g) is then diluted with purified water (220g), heated to $35\text{--}40^{\circ}\text{C}$ and then mixed with the drug suspension for 3 mins. Dispersion is then ceased, pH is adjusted to that of an optimum value, typically between 5 and 6, especially 5.5. The drug suspension
30 is then filtered through 100 mesh filters and stored prior to filling into clean

bottles. This procedure results in the components being present in the following concentrations:

	Micronised beclomethasone dipropionate anhydrate	0.1% (w/w)
5	Dextrose anhydrous	5.0% (w/w)
	Microcrystalline cellulose	
	and carboxymethylcellulose sodium (Avicel RC591)	1.5% (w/w)
	Phenylethyl alcohol	0.275% (v/w)
	Benzalkonium chloride solution 50% (w/v)	0.04% (v/w)
10	Glycerol	4.0% (w/w)
	Propylene glycol	1.0% (w/w)
	Polyoxyethylene (20) sorbitan monooleate	0.007% (w/w)
	Disodium hydrogen orthophosphate anhydrous	0.31% (w/w)
	Citric acid monohydrate	0.2% (w/w)
15	Purified water	to 100%.

Biological Data

The formulation of the present invention, Example 1 (beclomethasone dipropionate anhydrate aqueous nasal spray, hereinafter defined as BANS) which delivers 50 µg BDP in a single spray was tested in a variety of assays to deduce its effect upon nasal symptoms when compared with controls and a prior art formulation (Aldecin™ AQ).

25 1) Effect of BANS on TDI-induced nasal symptoms in sensitised guinea pigs.

Guinea pigs were immunised by 2 x 5 days intranasal application of 10% TDI (toluene 2, 4-diisocyanate) at intervals of 3 weeks. One or two weeks after the final sensitisation, a nasal allergy like response (sneeze, rhinorrhea, nasal obstruction) was provoked by intranasal application of 5% TDI. Drugs were

topically applied 0.5, 1 or 4 hr before the provocation (1 spray each nostril equivalent to 100 µg BDP), however, a control utilised animals sensitised with 5% TDI without drug treatment. Any nasal symptoms were then observed (eg. sneezing, rhinorrhea and nasal obstruction) and scored according to the criteria displayed in Table 1.

Table 1: Criteria used to assign a nasal symptom score for each group

Symptom	Score			
	0	1	2	3
Sneezing	Not observed	1-4	5-11	>12
Watery rhinorrhea	Dry nostril	Snivel observed, but remains within nostril	Snivel leaks from nostril and wets the nasolabial portion, but does not discharge	Snivel drops from the nose
Nasal obstruction	Not observed	Observed	-	-

The sum of the score was regarded as the nasal response of the animal and a 'mean score' value was given for the mean of the scores of each group. The results of this investigation are shown in Figure 4.

2) Effect of BANS on antigen induced nasal vascular permeability in sensitised rats.

Rats were immunised with DNP-As and the animals with 72 hr –PCA titre over x50 were used. Under the anaesthesia, the nasal cavity of the rat was perfused with saline. After the dye (4% pontamine sky blue (Brilliant blue) 5 ml/kg) was intravenously injected, the perfusate was collected for 10 min. Thereafter, the

antigen solution was perfused for 10 min followed by perfusion with saline for further 30 min. The dye concentration of the perfusate collected was determined by absorbance at 616nm. Drugs were topically applied 24hr and 1hr before the provocation (2 sprays at each time equivalent to 100µg BDP). Controls were prepared which utilised antigen challenged sensitised animals without drug treatment (control) and BANS placebo treatment (vehicle). The results of this investigation are shown in Figure 5.

3) Effect of BANS on the increase in intranasal pressure after antigen challenge in sensitised guinea pigs.

Guinea pigs were immunised with OVA by subcutaneous administration in mixture with FCA. The animals with 4 hr-PCA titre over x50 were used. Under the anaesthesia, a Y-shaped cannula was inserted into the trachea of larynx side. One end of the cannula was connected to the transducer to measure intranasal pressure and the other end to air bomb to supply contact flow of the air. After instillation of the antigen solution into the nose, intranasal pressure was measured for 28 min. Drugs were topically applied 24 hr and 1 hr before the provocation (4 sprays at each time equivalent to 200 µg BDP). Controls were prepared which utilised antigen challenged sensitised animals without drug treatment (control) and BANS placebo treatment (vehicle). The results of this investigation are shown in Figure 6.

4) Challenge test of BANS against Ps. Cepacia

Formulations corresponding to BANS and the same formulation containing only 0.02% (w/w) benzalkonium chloride as preservative (i.e. no phenylethyl alcohol) and the same formulation containing only 0.275% (v/w) phenylethylalcohol as preservative (i.e. no benzalkonium chloride) were challenged with an inoculum of Ps cepacia. The results, shown in Figure 7, demonstrate that the combined

preservative is much improved in respect of antimicrobial effectiveness relative to the two preservatives individually in this formulation.

Description of the drawings

5

Figure 1 contains a flow diagram to clearly describe the manufacturing process involved to produce a formulation of the present invention.

10

Figure 2 contains a cross section description of a suitable container for the formulation of the present invention.

Figure 3 contains a cross section diagram of a pump system (Valois VP3/50) with actuator suitable for use in a container such as that described in Figure 2.

15

Figure 4 compares the effect of BANS, Aldecin™ AQ and a control upon TDI-induced nasal symptoms at differing time intervals from drug administration.

20

Figure 5 compares the effect of BANS, Aldecin™ AQ, a vehicle and a control upon antigen induced nasal vascular permeability at a suitable time from drug administration.

25

Figure 6 compares the effect of BANS, Aldecin™ AQ, a vehicle and a control upon the increase in intranasal pressure from 0 to 28 minutes after antigen challenge.

30

Figure 7 shows the results of the challenge test of BANS and the same formulation without one of each of the two preservatives against Ps. cepacia.

Abbreviations

	BANS	beclomethasone dipropionate anhydrate aqueous nasal spray (following Example 1, except where indicated)
5	BDP	beclomethasone dipropionate
	TDI	toluene 2,4-diisocyanate
	FCA	Freund complete adjuvant
	PCA	Passive cutaneous anaphylaxis
	DNP-As	Ascari's suum extracts conjugated with dinitrophenol (antigen)
10	OVA	Ovalbumin (antigen)
	BKC	Benzalkonium chloride
	PEA	Phenylethyl alcohol

15 Throughout the specification and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and 'comprising', will be understood to imply the inclusion of a stated integer or step or group of integers but not to the exclusion of any other integer or step or group of integers or steps.

20 The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without
25 limitation, the following claims:

Claims

1. A pharmaceutical formulation which comprises an aqueous solution of carboxy methylcellulose sodium, glycerol, propylene glycol and polyoxyethylene (20) sorbitan monooleate, containing suspended therein particulate microcrystalline cellulose and beclomethasone dipropionate anhydrate, characterised in that said aqueous suspension further comprises:

Dextrose;

Phenylethyl alcohol;

Benzalkonium chloride;

Disodium hydrogen orthophosphate; and

Citric acid.

2. A pharmaceutical formulation according to claim 1 characterised in that it is buffered to a pH of between 5 and 6.

3. A pharmaceutical formulation according to claim 1 characterised in that it is isotonic with fluids of the nasal cavity.

4. A pharmaceutical formulation according to claim 1 having a composition as follows:

Micronised beclomethasone dipropionate anhydrate	0.1% (w/w)
Dextrose anhydrous	5.0% (w/w)
Microcrystalline cellulose	
and carboxymethylcellulose sodium (Avicel RC591)	1.5% (w/w)
Phenylethyl alcohol	0.275% (v/w)
Benzalkonium chloride solution 50% (w/v)	0.04% (v/w)
Glycerol	4.0% (w/w)
Propylene glycol	1.0% (w/w)

Polyoxyethylene (20) sorbitan monooleate	0.007% (w/w)
Disodium hydrogen orthophosphate anhydrous	0.31% (w/w)
Citric acid monohydrate	0.2% (w/w)
Purified water	to 100%.

5

5. A container comprising a pharmaceutical formulation according to claim 1 suitable for delivering it in the form of a nasal spray.

10

6. A pharmaceutical formulation according to claim 1 for use in the treatment or prophylaxis of allergic rhinitis.

7. Use of a pharmaceutical formulation according to claim 1 in the manufacture of a medicament for the treatment or prophylaxis of allergic rhinitis.

15

8. A method of treatment of allergic rhinitis which comprises administering to a patient a pharmaceutically acceptable amount of a formulation according to claim 1.

20

9. A process for preparing a formulation according to claim 1 as herein before described by reference to the manufacturing flow diagram shown in Figure 1.

Figure 1

15






Figure 2







Figure 3



.

.

.

.

Figure 4





Figure 5





.

.

.

.

Figure 6




Figure 7

Challenge Test of BANS against *Ps. cepacia*

	Log ₁₀ reduction *				
	Log ₁₀ innoculum count	2days	7days	14days	28days
BKC 0.02 %w/w	6.2	0.3	1.0	1.3	1.8
PEA 0.275 %v/w	6.2	0.2	0.6	1.7	NR
BKC 0.02 %w/w + PEA 0.275 %v/w	6.2	NR	NR	NR	NR

* : Log₁₀ reduction = Log₁₀ (innoculum count) - Log₁₀ (sample count)

NR : no recovery

THIS PAGE BLANK (USPTO)